Search Results for "lubiprostone"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for lubiprostone. Results 1 to 7 of 7 total matches.
See also: Amitiza
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
Chloride Channel Activator Lubiprostone – generic Amitiza (SpecGx) 8, 24 mcg caps 71.80 404.50 8 mcg bid ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721e | Show Introduction Hide Introduction
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
.
Lubiprostone (Amitiza, and generics), linaclotide (Linzess),
plecanatide (Trulance), or tenapanor (Ibsrela ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction
Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
nortriptyline amitriptyline fiber polyethylene glycol Miralax lubiprostone Amitiza Lotronex ...
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1 doi:10.58347/tml.2025.1721c | Show Introduction Hide Introduction
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
▶ Detected in minimal amounts in breast milk2
Lubiprostone (Amitiza) ▶ Avoid use
▶ No adequate studies ...
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-2 doi:10.58347/tml.2025.1721b | Show Introduction Hide Introduction
Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
, a secretagogue
such as lubiprostone (Amitiza, and generics),
linaclotide (Linzess), or plecanatide (Trulance ...
The FDA has approved tenapanor (Ibsrela - Ardelyx),
a sodium/hydrogen exchanger 3 (NHE3) inhibitor, for
twice-daily oral treatment of irritable bowel syndrome
with constipation (IBS-C) in adults. Tenapanor is the
first NHE3 inhibitor to become available in the US.
Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
(Trulance), and lubiprostone (Amitiza)
and the prokinetic drug prucalopride (Motegrity),
may be considered ...
The Vibrant orally administered vibrating capsule
(Vibrant Gastro), an FDA-cleared medical device, is
now available by prescription for treatment of adults
with chronic idiopathic constipation (CIC) who have
not experienced relief of their bowel symptoms
by using laxative therapies at the recommended
dosage for at least one month. It is the first drug-free
treatment to be authorized by the FDA for this
indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 doi:10.58347/tml.2023.1675a | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
.
They appear to be similar in efficacy and safety, but
no direct comparisons are available.13-15 Lubiprostone ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.